Andrew Steele is currently serving as the Director Translational Medicine Lead at Genmab, a position held since November 2023. Prior roles include Director of Precision Medicine and Clinical Biomarkers in Oncology at Regeneron from October 2022 to November 2023, with a specialization in Hematologic Malignancies. From April 2004 to November 2022, Andrew contributed as a paper and grant reviewer for multiple prestigious journals and grant-awarding bodies within the field of Hematology. Previous experience includes key roles at The Janssen Pharmaceutical Companies, University of Southampton, and Portola Pharmaceuticals, focusing on oncology translational research and leukemia and lymphoma. Educational credentials comprise a PhD in Molecular Microbiology and an M.Phil in Mycology from the University of Hertfordshire and University of Bedfordshire, respectively.
This person is not in any teams
This person is not in any offices